Alnylam: 3Q Earnings Snapshot
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $245.3 million in its third quarter.
The Cambridge, Massachusetts-based company said it had a loss of $2.43 per share. Losses, adjusted for stock option expense, came to $1.56 per share.
The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.73 per share.
The RNA interference drug developer posted revenue of $2.1 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $19.4 million.
Alnylam shares have decreased 32 percent since the beginning of the year. The stock has decreased 34 percent in the last 12 months.